Effect of lansoprazole and rabeprazole on dual-antiplatelet therapy in patients with coronary heart disease
10.3760/cma.j.issn.1673-4904.2013.31.003
- VernacularTitle:兰索拉唑和雷贝拉唑对冠心病患者双重抗血小板治疗作用的影响
- Author:
Zhe YAN
;
Ying DOU
;
Mingtai WANG
;
Fucheng SUN
- Publication Type:Journal Article
- Keywords:
Aspirin;
Platelet aggregation;
Clopidogrel;
Lansoprazole;
Rabeprazole
- From:
Chinese Journal of Postgraduates of Medicine
2013;36(31):7-9
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influence of proton pump inhibitors (lansoprazole and rabeprazole) on dual-antiplatelet therapy (DAPT) in patients with coronary heart disease.Methods One hundred and eighty-one cases of coronary heart disease with DAPT were selected,and they were divided into control group (66 cases,no proton pump inhibitors administered),lansoprazole group (65 cases,lansoprazole administered) and rabeprazole group (50 cases,rabeprazole administered).100 mg/day of aspirin and 75 mg/day of clopidogrel were concomitantly used in all patients.Platelet aggregation rate,platelet aggregation threshold index (PATI) and adenosine diphosphate (ADP) was measured.Results The ADP-PATI in control group was (3.47 ± 0.96) μ mol/L,lansoprazole group was (3.28 ± 1.05) μ mol/L,rabeprazole group was (3.32 ±0.83) μ mol/L,and there was no statistically significant difference among three groups (P＞0.05).There was also no statistically significant difference in platelet aggregation rate and collagen-PATI among three groups (P ＞ 0.05).Conclusion In patients with coronary artery disease,the concomitant use of lansoprazole or rabeprazole does not affect antiplatelet action during DAPT.
